Complete report on Fluocinolone
Acetonide market divided into 11 major chapters that offer an overview of current market scenario as well as Fluocinolone
Acetonide forecasts is now available at http://www.
RNIB eye health campaigns manager, Clara Eaglen, said: "We are pleased that NICE has published its Appraisal Consultation Document recommending the use of fluocinolone
acetonide for the treatment of chronic diabetic macular oedema (DMO) in certain cases.
Its advanced product candidate, Iluvien(R), is an intravitreal insert containing fluocinolone
acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.
Acetonide scalp oil, body oil and ear drops are now shipping and available through wholesalers-distributors as well as directly to the trade.
pSivida's lead development product, Iluvien[TM], delivers fluocinolone
acetonide (FA) for the treatment of diabetic macular edema (DME).
ILUVIEN is Alimera's sustained release intravitreal implant that delivers sub-microgram levels of fluocinolone
acetonide (FAc) for up to 36 months for the treatment of chronic DME.
The Medidur(TM) product delivers fluocinolone
acetonide to treat diabetic macular edema (DME) which we consider to be a major ophthalmic market opportunity.
Each ILUVIEN implant provides a therapeutic effect for up to 36 months by delivering sustained sub-microgram levels of the corticosteroid, fluocinolone
Founded by an executive team with extensive development and revenue growth expertise, Alimera initiated a Phase III clinical trial in October 2005 to study diabetic macular edema (DME) patients treated using Medidur[TM] with fluocinolone
acetonide, the company's pharmacologic treatment for DME.
Food and Drug Administration for its abbreviated new drug applications for fluocinolone
acetonide scalp oil, 0.
Cream contains a clinically-proven formula which combines three active ingredients: fluocinolone
Retisert(TM) is surgically placed into the back of the eye and releases the steroid, fluocinolone
acetonide at a constant rate over a period of up to 30 months.